Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

MEDIBIO LIMITED

INVESTOR PRESENTATION - MEDIBIO LIMITED

ASX:MEB

MEDIBIO LIMITED

Health Care

Medibio Limited (MEB, formerly BioProspect Limited) is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This tests utilise circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression and other mental health disorders and chronic stress Former Names Bioprospect Limited (BPO), 28/11/2014

Read more

Market Cap

14.82m

Price at Close

$0.011

4w avg. Volume

6.41m

4w avg. Turnover

$71.76k

Announcements
announcementt+2 movementdate
  • Updated Capital Structure

    Issued Capital

  • -

    27 Oct 2020

-

27 Oct 2020
  • Revised Securities Trading Policy

    Other

  • +9.09%

    15 Oct 2020

+9.09%

15 Oct 2020
  • Appendix 3G

    Issued Capital

  • -9.09%

    09 Oct 2020

-9.09%

09 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • -9.09%

    09 Oct 2020

-9.09%

09 Oct 2020
  • MEB Signs Clinical Trial Agreement with MedBridge Healthcare

    Progress Report · Market sensitive

  • +10.00%

    06 Oct 2020

+10.00%

06 Oct 2020
  • Request For FDA Breakthrough Device Designation Submitted

    Progress Report · Market sensitive

  • 0.00%

    01 Oct 2020

0.00%

01 Oct 2020
  • 2020 Annual Report

    Periodic Reports

  • 0.00%

    25 Sep 2020

0.00%

25 Sep 2020
  • Appendix 4G and Corporate Governance Statement

    Periodic Reports

  • 0.00%

    25 Sep 2020

0.00%

25 Sep 2020
  • FDA Strategy and Regulatory Update

    Progress Report · Market sensitive

  • -8.33%

    31 Aug 2020

-8.33%

31 Aug 2020
  • Appendix 4E and Preliminary Final Report

    Periodic Reports · Market sensitive

  • 0.00%

    28 Aug 2020

0.00%

28 Aug 2020
Market Data

Current Price

$0.011

52WK HIGH

$0.017

52WK LOW

$0.005

1YR RETURN

0.00%

1YR RETURN VS. SECTOR

-19.09%

90 DAY RETURN

-21.43%

ASX RANK

1,561

/2,015

SECTOR RANK

39

/47

SHARES OUTSTANDING

1.35b
ASX:MEB

MEDIBIO LIMITED

Health Care

Medibio Limited (MEB, formerly BioProspect Limited) is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This tests utilise circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression and other mental health disorders and chronic stress Former Names Bioprospect Limited (BPO), 28/11/2014

Read more

Market Cap

14.82m

Price at Close

$0.011

4w avg. Volume

6.41m

4w avg. Turnover

$71.76k

ASX:MEB is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.